UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) is taking strategic steps to capitalize on the opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) by adjusting its team structure and changing personnel.
New Divisional Leadership for GBA Expansion
AstraZeneca will split its respiratory, digestive, and autoimmune business unit into two distinct divisions to better serve the region. The first division will focus on respiratory inhalation and biological products, led by Lin Xiao. The second division will concentrate on respiratory nebulization, digestion, vaccines and immunotherapy, and autoimmunity, headed by Chen Xi. This reorganization aims to streamline operations and enhance AstraZeneca’s presence in the GBA.
Leadership Appointments and Regional Representation
Lin Xiao will also assume the role of head for the Hong Kong and Macau regions and serve as the Senior Management Team (SMT) spokesperson for the southern region of the company. Chen Xi, in addition to leading the second division, serves as Vice President and SMT member of AstraZeneca China, reporting to Mr. Lai Minglong, General Manager of AstraZeneca China. These appointments underscore AstraZeneca’s commitment to the GBA and its strategic importance within the company’s global operations.-Fineline Info & Tech
